Oral selective JAK1 inhibitors such as upadacitinib, abrocitinib, and ivarmacitinib, and the dual JAK1/JAK2 inhibitor baricitinib, provide systemic control for moderate-to-severe AD. Here, JAK2 is linked to Alzheimer disease.